Capital Expenditures - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.1 PLN -1.64% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Capital Expenditures Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Capital Expenditures
-zł188.5m
CAGR 3-Years
-80%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Medicofarma Biotech SA
WSE:MDB
Capital Expenditures
-zł1.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Capital Expenditures
-zł61.8m
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Capital Expenditures?
Capital Expenditures
-188.5m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Capital Expenditures amounts to -188.5m PLN.

What is Ryvu Therapeutics SA's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-49%

Over the last year, the Capital Expenditures growth was -764%. The average annual Capital Expenditures growth rates for Ryvu Therapeutics SA have been -80% over the past three years , -49% over the past five years .

Back to Top